What are the chemotherapy regimens used to treat recurrent platinum-resistant fallopian tube carcinoma?

Updated: Aug 20, 2019
  • Author: from Memorial Sloan-Kettering - Elizabeth L Jewell, MD, MHSc; Chief Editor: from Memorial Sloan-Kettering - Yukio Sonoda, MD  more...
  • Print


Platinum-resistant disease:

For a recurrence that develops less than 6 months after the completion of initial therapy, one of the following single-agent regimens may be considered:

  • Pegylated liposomal doxorubicin 50 mg/m 2 IV infused over 30 min every 21 d [18]   or
  • Topotecan 1.25 mg/m 2 IV infused over 30 min on days 1-5 every 21 d [18]   or
  • Gemcitabine 1000 mg/m 2 IV infused over 30 min on days 1 and 8 every 21 d [19]
  • Other agents listed in the NCCN guidelines [4]

In November 2014, the US Food and Drug Administration (FDA) approved bevacizumab (Avastin) for platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or peritoneal cancers in patients who received no more than two prior chemotherapy regimens. It is indicated in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan. [20]  

The bevacizumab regimen consists of the following:

  • Bevacizumab 10 mg/kg IV every 14 d in combination with one of the following IV chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (topotecan is given weekly) [20]  or

  • Bevacizumab 15 mg/kg IV every 21 d in combination with topotecan (every 21 d) [20]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!